Patient pharmacodynamic biomarker and pk evaluation results from an ongoing phase I dose-escalation study of q702, an axl, mer and csf1r kinase inhibitor in patients with advanced solid tumors

被引：2
|
作者：
Choi, Bae Jung
Devalingam, Devalingam
Alistar, Angela
El-Khoueiry, Anthony
Mita, Alain
Kang, Hwankyu
Choi, Jinho
Ahn, Hyunji
Kim, Jeongjun
Lee, Seung-Joo
Yang, Yeong-In
Ahn, Jiye
Jeon, Borami
Kim, Jaeseung
Nam, Kiyean
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2255
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2255
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: Preliminary results
    Jones, S. F.
    Burris, H. A., III
    Dumez, H.
    Infante, J. R.
    Fowst, C.
    Gerletti, P.
    Xu, H.
    Jakubczak, J.
    Mellaerts, N.
    Schoffski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors
    Kang, Zhuang
    Li, Shenglan
    Lin, Yi
    Li, Yongsheng
    Mao, Ying
    Zhang, Jing
    Lei, Ting
    Wang, Haidan
    Su, Yangzhi
    Yang, Yang
    Qiu, Jingbo
    Li, Wenbin
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (02) : 296 - 305
  • [3] A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors
    Zhuang Kang
    Shenglan Li
    Yi Lin
    Yongsheng Li
    Ying Mao
    Jing Zhang
    Ting Lei
    Haidan Wang
    Yangzhi Su
    Yang Yang
    Jingbo Qiu
    Wenbin Li
    Investigational New Drugs, 2023, 41 : 296 - 305
  • [4] A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.
    Alistar, Angela Tatiana
    El-Khoueiry, Anthony B.
    Mahalingam, Devalingam
    Mita, Monica M.
    Kang, Hwankyu
    Yang, Yeong-In
    Ahn, Jiye
    Kim, Jeongjun
    Choi, Baejung
    Jeon, Yeejin
    Jung, Chunwon
    Jeon, Borami
    Kim, Jaeseung
    Nam, Kiyean
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] A phase I dose-escalation and pk study of continuous oral rucaparib in patients with advanced solid tumors
    Flynn, M.
    Shapiro, G.
    LoRusso, P.
    Kristeleit, R.
    Patel, M.
    Infante, J.
    Giordano, H.
    Borrow, J.
    Jaw-Tsai, S.
    Burris, H., III
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S185 - S185
  • [6] Q702, selective Axl, Mer and CSF1R triple kinase inhibitor with dual potentials leading to tumor regression: Immuno-oncology therapy and targeted cancer therapy
    Yang, Yeong-In
    Kang, Hwankyu
    Park, Dongsik
    Jeon, Yeejin
    Kim, Jeongjun
    Choi, Baejung
    Kim, Jaeseung
    Rho, Jinkyung
    Lee, Jaecheol
    Nam, Kiyean
    CANCER RESEARCH, 2019, 79 (13)
  • [7] A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors
    Molife, L. Rhoda
    Dean, Emma Jane
    Blanco-Codesido, Montserrat
    Krebs, Matthew G.
    Brunetto, Andre T.
    Greystoke, Alastair Peter
    Daniele, Gennaro
    Lee, Lucy
    Kuznetsov, Galina
    Myint, Khin Than
    Wood, Karen
    de las Heras, Begona
    Ranson, Malcolm Richard
    CLINICAL CANCER RESEARCH, 2014, 20 (24) : 6284 - 6294
  • [8] A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.
    Kristeleit, Rebecca Sophie
    Shapiro, Geoffrey
    LoRusso, Patricia
    Infante, Jeffrey R.
    Flynn, Michael
    Patel, Manish R.
    Tolaney, Sara M.
    Hilton, John Frederick
    Calvert, Alan Hilary
    Giordano, Heidi
    Isaacson, Jeffrey D.
    Borrow, Jennifer
    Allen, Andrew R.
    Jaw-Tsai, Sarah S.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors
    Schoeffski, P.
    Dumez, H.
    Jones, S. F.
    Fowst, C.
    Gerletti, P.
    Xu, H.
    Jakubczak, J.
    Infante, J.
    Mellaerts, N.
    Burris, H. A.
    EJC SUPPLEMENTS, 2008, 6 (12): : 91 - 91
  • [10] First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors
    Azaro, A.
    Rodon, J.
    Herranz, M.
    Nuciforo, P.
    Prudkin, L.
    Lopez-Busto, N.
    Balandraud, S.
    Cattan, V.
    Jacquet-Bescond, A.
    Marfai, L.
    Pauly, J.
    Postel-Vinay, S.
    Hollebecque, A.
    Soria, J. C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S54 - S54
12345